Autumn Glory Partners LLC Boosts Position in Eli Lilly and Company $LLY

Key Points

• Autumn Glory Partners LLC increased its holdings in Eli Lilly and Company by 48.5% during the second quarter, owning 1,044 shares worth approximately $814,000 at that time.
• Several other hedge funds have also ramped up their investments, with Fishman Jay A Ltd. MI raising its stake by 54.2% and PUREfi Wealth LLC by 70.4% in the same period.
• Eli Lilly reported $6.31 EPS for the quarter, exceeding analysts' expectations, and has set a fiscal year 2025 guidance of 21.750-23.000 EPS.

Autumn Glory Partners LLC boosted its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 48.5% during the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 1,044 shares of the company's stock after buying an additional 341 shares during the period. Autumn Glory Partners LLC's holdings in Eli Lilly and Company were worth $814,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the business. Fishman Jay A Ltd. MI raised its holdings in Eli Lilly and Company by 54.2% in the second quarter. Fishman Jay A Ltd. MI now owns 6,094 shares of the company's stock valued at $4,750,000 after buying an additional 2,143 shares during the period. PUREfi Wealth LLC raised its holdings in Eli Lilly and Company by 70.4% in the second quarter. PUREfi Wealth LLC now owns 2,190 shares of the company's stock valued at $1,707,000 after buying an additional 905 shares during the period. Vantage Investment Partners LLC raised its holdings in Eli Lilly and Company by 2.9% in the second quarter. Vantage Investment Partners LLC now owns 49,006 shares of the company's stock valued at $38,202,000 after buying an additional 1,363 shares during the period. Plimoth Trust Co. LLC grew its position in Eli Lilly and Company by 4.7% in the second quarter. Plimoth Trust Co. LLC now owns 8,180 shares of the company's stock valued at $6,377,000 after acquiring an additional 367 shares in the last quarter. Finally, Woodmont Investment Counsel LLC grew its position in Eli Lilly and Company by 53.4% in the second quarter. Woodmont Investment Counsel LLC now owns 19,910 shares of the company's stock valued at $15,520,000 after acquiring an additional 6,933 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company's stock.

Insider Buying and Selling

In related news, Director Jamere Jackson acquired 200 shares of the business's stock in a transaction that occurred on Friday, August 8th. The shares were acquired at an average cost of $639.56 per share, for a total transaction of $127,912.00. Following the completion of the purchase, the director directly owned 9,402 shares in the company, valued at $6,013,143.12. This trade represents a 2.17% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Gabrielle Sulzberger acquired 117 shares of the business's stock in a transaction that occurred on Tuesday, August 12th. The shares were bought at an average price of $641.18 per share, for a total transaction of $75,018.06. Following the completion of the purchase, the director owned 2,703 shares of the company's stock, valued at approximately $1,733,109.54. This represents a 4.52% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders purchased a total of 4,514 shares of company stock valued at $2,894,841 in the last three months. 0.13% of the stock is owned by corporate insiders.

Eli Lilly and Company Stock Performance

Shares of LLY opened at $840.46 on Monday. The business's fifty day moving average price is $734.60 and its 200 day moving average price is $765.44. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $937.00. The stock has a market capitalization of $795.46 billion, a PE ratio of 54.93, a price-to-earnings-growth ratio of 1.17 and a beta of 0.47. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.59 by $0.72. The company had revenue of $15.56 billion for the quarter, compared to analysts' expectations of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The firm's quarterly revenue was up 37.6% compared to the same quarter last year. During the same period last year, the business posted $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Equities research analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Analysts Set New Price Targets

Several analysts have issued reports on the stock. Morgan Stanley lowered their price objective on shares of Eli Lilly and Company from $1,028.00 to $1,023.00 and set an "overweight" rating for the company in a research report on Friday. Leerink Partners reaffirmed a "market perform" rating and issued a $715.00 price objective on shares of Eli Lilly and Company in a research report on Thursday, August 7th. Daiwa America downgraded shares of Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research report on Sunday, August 17th. JPMorgan Chase & Co. lowered their price objective on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set an "overweight" rating for the company in a research report on Tuesday, September 16th. Finally, Cantor Fitzgerald lowered their price objective on shares of Eli Lilly and Company from $975.00 to $825.00 and set an "overweight" rating for the company in a research report on Wednesday, August 13th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and ten have given a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $938.94.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.